Prelude Therapeutics (PRLD) 10-K2024 FY Annual report

Filed: 10 Mar 25, 7:50am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: abdominal, AI, antigen, appetite, artificial, ASH, AUC, bad, BID, biopsy, Biosecure, blood, bystander, Chinese, CLIA, Cmax, CODM, combat, compliant, conjugated, deeper, developmental, Disaggregation, DLT, ESMO, esophageal, EUR, excise, exquisite, forecast, forecasting, fourteen, Freeze, FTC, Gan, gastric, GBP, Gen, Haiyan, hypotension, IFN, ineligible, innate, intact, intelligence, Japanese, JCC, KEYTRUDA, LDT, Lee, length, levy, lingering, lymphoid, mainland, margin, Maryland, membrane, Merck, MHC, military, missense, misuse, mouse, multiregional, Nanjing, network, Nurix, older, Oncopia, pace, pain, parent, partly, payload, PBMC, PD, pembrolizumab, picomolar, piece, platform, Plexium, poster, presidential, rasburicase, RECIST, renegotiated, resilience, resiliency, resume, retaliatory, Science, scrutinizing, session, Shanghai, shrinkage, standalone, step, sublicensable, successor, sum, supervisory, Suzhou, Symposium, Taiwan, Taiwanese, TCL, tension, theft, TLS, TPD, UK, unapproved, unqualified, upfront, upper, usage, voluntarily, VUS, Zaiming, Zanrong

Removed: AbbVie, abemaciclib, aberrant, abnormal, activation, acute, adaptive, alter, altered, AML, anniversary, barrier, BBB, cellular, CNS, comparison, compel, conditional, Constellation, Coordinated, depleted, Diamond, division, endocrine, entry, epidermal, ER, evade, evidenced, evolved, fierce, flexible, Fochon, GBM, genome, glioblastoma, Historically, Ideaya, imprecise, induced, intensively, interfering, investigated, IPO, Kura, leukemia, localized, malignant, master, maximal, Mirati, modality, myeloid, nanomolar, noncompliant, noted, Nuvation, orthotopic, penetrate, phosphorylation, potently, ratio, RB, receptor, regression, Relay, renewed, Repare, resection, revealed, Revolution, ribociclib, spread, Sprint, Stark, subfamily, substrate, suggesting, Syndax, Tango, upregulation, wider, xenograft

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PRLD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Krishna Vaddi, Chief Executive Officer of Prelude Therapeutics Incorporated (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: March 10, 2025	/s/ Krishna Vaddi
	Krishna Vaddi, Ph.D.
	Chief Executive Officer and Director (Principal Executive Officer)